Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 1 (6) , 411-420
- https://doi.org/10.2165/00129784-200101060-00001
Abstract
Treatment with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has been accompanied by a reduced risk of cardiovascular events. Rapid onset of clinical benefit and weak correlations...Keywords
This publication has 88 references indexed in Scilit:
- NF-κB: pivotal mediator or innocent bystander in atherogenesis?Journal of Clinical Investigation, 2001
- Relations of lipoprotein subclass levels and LDL size to reduction in coronary atherosclerosis in the PLAC I trialAtherosclerosis, 2000
- Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cellsAtherosclerosis, 1999
- Inhibition of proinflammatory cytokine production by pravastatinThe Lancet, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery diseaseThe American Journal of Cardiology, 1995
- Protein Lipidation in Cell SignalingScience, 1995
- Immune mechanisms in atherosclerosis.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1989
- Platelet function and survival in patients wit severe hypercholesterolemia.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1981